Menu
Search
|

Menu

Close
X

Immune Design Corp IMDZ.OQ (NASDAQ Stock Exchange Global Market)

4.35 USD
-0.30 (-6.45%)
As of 1:30 AM IST
chart
Previous Close 4.65
Open 4.65
Volume 19,831
3m Avg Volume 46,780
Today’s High 4.65
Today’s Low 4.32
52 Week High 13.00
52 Week Low 2.80
Shares Outstanding (mil) 25.62
Market Capitalization (mil) 269.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
7
FY16
13
FY15
10
EPS (USD)
FY18
-0.276
FY17
-1.847
FY16
-2.488
FY15
-2.067
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
16.35
5.73
Price to Book (MRQ)
vs sector
3.65
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-66.38
14.61
Return on Equity (TTM)
vs sector
-66.44
16.34

EXECUTIVE LEADERSHIP

Edward Penhoet
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Carlos Paya
President, Chief Executive Officer, Director, Since 2011
Salary: $557,025.00
Bonus: --
Stephen Brady
Executive Vice President, Strategy & Finance, Since 2015
Salary: $347,550.00
Bonus: --
Sergey Yurasov
Senior Vice President, Clinical Development, and Chief Medical Officer, Since 2016
Salary: --
Bonus: --
Jan Ter Meule
Chief Scientific Officer, Since 2013
Salary: $363,204.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1616 Eastlake Ave E Ste 310
SEATTLE   WA   98102-3739

Phone: +1650.3928350

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

SPONSORED STORIES